“The absence of any approved norovirus treatments or vaccines creates a substantial market opportunity for Cocrystal,” said James Martin, Cocrystal's CFO and co-CEO. “ With 685 million global cases ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratu ...

Traws to host a Q2 2025 business update call today, August 14th at 8:30 AM ET ...